{"id":16297,"date":"2023-07-11T22:18:00","date_gmt":"2023-07-11T14:18:00","guid":{"rendered":"https:\/\/flcube.com\/?p=16297"},"modified":"2024-12-02T22:21:41","modified_gmt":"2024-12-02T14:21:41","slug":"everest-medicines-and-sinopharm-group-ink-mou-to-enhance-distribution-and-collaboration","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=16297","title":{"rendered":"Everest Medicines and Sinopharm Group Ink MoU to Enhance Distribution and Collaboration"},"content":{"rendered":"\n

China-based Everest Medicines (HKG: 1952) has announced the signing of a memorandum of understanding (MoU) with Sinopharm Group Co., Ltd. The partnership aims to capitalize on Sinopharm’s supply chain service advantages in distribution, access, and retailing for Everest’s listed products within mainland China. The collaboration will also explore new product imports and novel business cooperation opportunities, although no financial details were disclosed.<\/p>\n\n\n\n

Leveraging Sinopharm’s Supply Chain for Everest’s Products<\/strong>
Everest Medicines, with its two approved products, Trodelvy (sacituzumab govitecan), a TROP-2 targeted antibody drug conjugate (ADC), and Xerava (eravacycline), an anti-infection drug, seeks to enhance its market presence in China. Trodelvy, approved in China in March 2023, is being prepared for commercial launch in the mainland market.<\/p>\n\n\n\n

Future Product Launches and Pipeline Expansion<\/strong>
The company plans to launch three more products in China within the next two years, reflecting its commitment to expanding access to innovative treatments. These include Nefecon (targeted-release formulation-budesonide), an IgA nephropathy therapy expected to win approval later this year, cefepime, and taniborbactam with an NDA filing for complicated urinary tract infection expected within this year. Additionally, etrasimod, an oral S1P modulator that has shown positive Phase III clinical results, is part of Everest’s pipeline.-Fineline Info & Tech<\/a><\/p>\n\n\n\n

<\/p>\n","protected":false},"excerpt":{"rendered":"

China-based Everest Medicines (HKG: 1952) has announced the signing of a memorandum of understanding (MoU)…<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":false,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,10],"tags":[30,126,1164,2311],"class_list":["post-16297","post","type-post","status-publish","format-standard","hentry","category-company","category-deals","tag-biotech","tag-everest-medicines","tag-hkg-1952","tag-sinopharm-group-company"],"yoast_head":"\nEverest Medicines and Sinopharm Group Ink MoU to Enhance Distribution and Collaboration - Insight, China's Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"China-based Everest Medicines (HKG: 1952) has announced the signing of a memorandum of understanding (MoU) with Sinopharm Group Co., Ltd. The partnership aims to capitalize on Sinopharm's supply chain service advantages in distribution, access, and retailing for Everest's listed products within mainland China. The collaboration will also explore new product imports and novel business cooperation opportunities, although no financial details were disclosed.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=16297\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Everest Medicines and Sinopharm Group Ink MoU to Enhance Distribution and Collaboration\" \/>\n<meta property=\"og:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=16297\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China's Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2023-07-11T14:18:00+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2024-12-02T14:21:41+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2560\" \/>\n\t<meta property=\"og:image:height\" content=\"1894\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=16297#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=16297\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Everest Medicines and Sinopharm Group Ink MoU to Enhance Distribution and Collaboration\",\"datePublished\":\"2023-07-11T14:18:00+00:00\",\"dateModified\":\"2024-12-02T14:21:41+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=16297\"},\"wordCount\":218,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"keywords\":[\"Biotech\",\"Everest Medicines\",\"HKG: 1952\",\"Sinopharm Group Company\"],\"articleSection\":[\"Company\",\"Deals\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=16297#respond\"]}],\"copyrightYear\":\"2023\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=16297\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=16297\",\"name\":\"Everest Medicines and Sinopharm Group Ink MoU to Enhance Distribution and Collaboration - Insight, China's Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"datePublished\":\"2023-07-11T14:18:00+00:00\",\"dateModified\":\"2024-12-02T14:21:41+00:00\",\"description\":\"China-based Everest Medicines (HKG: 1952) has announced the signing of a memorandum of understanding (MoU) with Sinopharm Group Co., Ltd. The partnership aims to capitalize on Sinopharm's supply chain service advantages in distribution, access, and retailing for Everest's listed products within mainland China. The collaboration will also explore new product imports and novel business cooperation opportunities, although no financial details were disclosed.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=16297#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=16297\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=16297#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Everest Medicines and Sinopharm Group Ink MoU to Enhance Distribution and Collaboration\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Everest Medicines and Sinopharm Group Ink MoU to Enhance Distribution and Collaboration - Insight, China's Pharmaceutical Industry","description":"China-based Everest Medicines (HKG: 1952) has announced the signing of a memorandum of understanding (MoU) with Sinopharm Group Co., Ltd. The partnership aims to capitalize on Sinopharm's supply chain service advantages in distribution, access, and retailing for Everest's listed products within mainland China. The collaboration will also explore new product imports and novel business cooperation opportunities, although no financial details were disclosed.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=16297","og_locale":"en_US","og_type":"article","og_title":"Everest Medicines and Sinopharm Group Ink MoU to Enhance Distribution and Collaboration","og_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","og_url":"https:\/\/flcube.com\/?p=16297","og_site_name":"Insight, China's Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2023-07-11T14:18:00+00:00","article_modified_time":"2024-12-02T14:21:41+00:00","og_image":[{"width":2560,"height":1894,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","type":"image\/jpeg"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=16297#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=16297"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Everest Medicines and Sinopharm Group Ink MoU to Enhance Distribution and Collaboration","datePublished":"2023-07-11T14:18:00+00:00","dateModified":"2024-12-02T14:21:41+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=16297"},"wordCount":218,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"keywords":["Biotech","Everest Medicines","HKG: 1952","Sinopharm Group Company"],"articleSection":["Company","Deals"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=16297#respond"]}],"copyrightYear":"2023","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=16297","url":"https:\/\/flcube.com\/?p=16297","name":"Everest Medicines and Sinopharm Group Ink MoU to Enhance Distribution and Collaboration - Insight, China's Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"datePublished":"2023-07-11T14:18:00+00:00","dateModified":"2024-12-02T14:21:41+00:00","description":"China-based Everest Medicines (HKG: 1952) has announced the signing of a memorandum of understanding (MoU) with Sinopharm Group Co., Ltd. The partnership aims to capitalize on Sinopharm's supply chain service advantages in distribution, access, and retailing for Everest's listed products within mainland China. The collaboration will also explore new product imports and novel business cooperation opportunities, although no financial details were disclosed.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=16297#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=16297"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=16297#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Everest Medicines and Sinopharm Group Ink MoU to Enhance Distribution and Collaboration"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/16297","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=16297"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/16297\/revisions"}],"predecessor-version":[{"id":16298,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/16297\/revisions\/16298"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=16297"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=16297"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=16297"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}